Liquid biopsy testing to identify, monitor, and predict recurrence in urothelial carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will collect serial blood and urine samples from people with suspected or confirmed urothelial carcinoma and analyze circulating tumor DNA (ctDNA), urine tumor DNA (utDNA), exosomes, and protein biomarkers. Researchers will compare these molecular signals with clinical findings, imaging, and pathology to determine their relationship to diagnosis, therapeutic response, and recurrence. The study emphasizes combining multiple biomarker types to improve sensitivity and specificity versus single-analyte tests. Resulting data may be used to develop predictive algorithms or signatures for recurrence risk and monitoring.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Suspected or histologically confirmed urothelial carcinoma

Exclusion Criteria:

* History of or concurrent active malignancy other than urothelial carcinoma

Where it's running

• The second hospital of Tianjin Medical University
  Tianjin, China Recruiting

Study contacts

• Study coordinator: Hailong Hu, MD
• Email: huhailong@tmu.edu.cn
• Phone: +8613662096232

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Trop2-targeted NIR-II probe to identify bladder cancer in ex vivo samples

  A phase 2 study tests whether a Trop2-targeted NIR-II fluorescent probe can highlight bladder cancer lesions on ex vivo bladder tissue from patients undergoing radical cystectomy.

  Recruiting Phase 2 Yunnan Cancer Hospital · Kunming, Yunnan · NCT07848854

• First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors

  This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.

  Recruiting at 3 sites Phase 1 Sutro Biopharma, Inc. · Orlando, Florida and 5 other locations · NCT07807345

• Blood test for detecting tumor DNA in bladder and upper tract cancer

  A blood test that looks for tumor DNA in people with muscle-invasive bladder cancer or upper tract urothelial cancer is being tested to see if it matches what’s found in tumor tissue and if it can help track recurrence or remission over two years.

  Recruiting AZ Sint-Lucas Gent · Ghent, East Flanders · NCT07756437

• Intravesical UGN-501 for Recurrent NMIBC (Phase 1, dose-escalation)

  This study tests whether UGN-501 can be safely given into the bladder to treat adults with recurrent non-muscle invasive bladder cancer.

  Recruiting at 6 sites Phase 1 UroGen Pharma Ltd. · Queen Creek, Arizona and 14 other locations · NCT07725796

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.